Impedance plethysmography IPG
DeviceIPG signal is measured with ThrombUS+ prototype device
Other names: IPG
NCT Number: NCT07665320
The purpose of this study is to collect data on blood circulation using a multi-frequency impedance plethysmography device developed in the ThrombUS+ project. Impedance plethysmography (IPG) is a non-invasive method that measures changes in blood volume using electrodes placed on the skin. The collected data will be used for device development, the improvement of diagnostic data analysis methods, and AI training.
A total of 40 participants will be recruited for this study, with 20 healthy volunteers in Tampere University and 20 patients undergoing thrombolytic therapy for DVT at Tampere University Hospital.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Tampere University, Tampere, Finland
This study aims to collect IPG data set from healthy volunteers and DVT patients using ThrombUS+ prototype device developed during the project and commercial IPG device as a reference. The data will be used to develop ThrombUS+ IPG device, its signal processing and analysis algorithms and to train ML models.
Objectives of the study are to
Secondary objectives are
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for Patients group:
Exclusion criteria
for Patients group:
Inclusion criteria
for Healthy volunteers group:
Exclusion criteria
for Healthy volunteers group:
IPG signal is measured with ThrombUS+ prototype device
Other names: IPG
In VOP measurement, a temporal blood restriction is caused by an occlusive cuff blocking venous outflow but allowing arterial inflow. The cuff intervention causes a change in venous blood volume, and it can be measured by electrical impedance plethysmography (IPG).
Other names: VOP
The first exercise is the Valsalva maneuver, where the subject first inhales and then pushes out the breath while the larynx is closed. In the second exercise, the subject inhales for approximately 10 seconds, holds the breath for approximately 5 seconds, and then breathes out. Finally, the subject moves the ankles to contract calf muscles, and further to cause changes in venous blood volume. The IPG signal is measured on both calves by ThrombUS+ prototype device during these exercises.
Other names: Valsalva
Time frame: From enrollment to the end of the CDT treatment (up to 2 days)
Time frame: From enrollment to the end of measurements (up to 2 hours)
Contact information is provided by the study sponsor or research team.
Tampere University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07102160
Cardiovascular Diseases, Deep Vein Thrombosis (DVT)
Fort Lauderdale, Florida, United States
View Trial DetailsNCT07439991
Cardiovascular Diseases, Deep Vein Thrombosis (DVT)
Changchun, Jilin, China
View Trial DetailsNCT06909240
Behavior, Cardiovascular Diseases
Hvidovre, Capital Region, Denmark
View Trial DetailsNCT02156401
Cardiovascular Diseases, Deep Vein Thrombosis (DVT)
Mainz, Rhineland-Palatinate, Germany
View Trial Details